Nonarticular and Regional Musculoskeletal Disorders

Dara M., 39, a hairdresser on her feet ten hours a day, has fibromyalgia where her fatigue, mood, and sleep pattern each point toward a different one of the three FDA-approved drugs. The disagreement is which single symptom should actually break the tie.

Priya K., 51, has fibromyalgia that hasn't responded to two approved agents, and low-dose naltrexone once looked like a promising next step. The largest randomized trial ever run on it has since reported negative — and the room has to decide what that actually changes.

Walter S., 58, developed complex regional pain syndrome after a simple wrist fracture, and his bone scan points toward a bisphosphonate. The disagreement is that the specific bisphosphonate with the best evidence isn't actually available here as a prescription — only as a clinical trial.

Foster T., 46, has chronic CRPS that's outlasted two standard treatment courses, and low-dose naltrexone is the next idea on the table. The disagreement is whether evidence that's genuinely contested even in fibromyalgia can fairly be borrowed for a diagnosis where it's never been tested at all.

Renata O., 52, an accountant hunched over dual monitors all day, has trigger-point pain that responds about equally well to dry needling and local anesthetic injection in the literature. The disagreement is whether that equivalence means the needle is doing all the work, or whether botulinum toxin can still earn its place.

Consuela R., 61, who never misses cooking Sunday dinner for her grandchildren, has frozen shoulder that responds well to corticosteroid injection in the literature — except her diabetes makes even a targeted joint injection a real glycemic gamble.

Marcus V., 47, training for a half marathon eight weeks out, has Achilles tendon pain that the fastest-acting treatment could actually rupture. The disagreement is whether his race deadline justifies that risk, or whether the slower, safer option is the only honest answer.

Bettina H., 58, has held a stable, low tramadol dose for eleven years for fibromyalgia she's managed since before opioid-stewardship guidance existed. The disagreement is whether tapering her now actually serves a guideline that, read closely, never told anyone to stop a drug like hers in a patient like her.

Harold P., 63, a retired carpenter, has had carpal tunnel symptoms respond to a corticosteroid injection once before — and a new EMG now shows actual nerve damage setting in. The disagreement is whether one more injection is still a reasonable bridge, or whether the nerve itself has already decided the question.